Zhenyu Cheng

Title: Zhenyu Cheng: Innovator in Cancer Research

Introduction

Zhenyu Cheng is a notable inventor based in Waterloo, Canada. He has made significant contributions to the field of cancer research through his innovative work. His research focuses on the use of polynucleotides to induce apoptosis in cancer cells, which has the potential to improve cancer treatment outcomes.

Latest Patents

Zhenyu Cheng holds a patent titled "Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells." This invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down the expression of the endogenous gene in a host. It also involves the delivery of a polynucleotide encoding the gene in a delivery vehicle or expression vector to provide expression in the host of the protein encoded by the polynucleotide. The invention highlights a truncated form of eIF-5A1 that is useful for inducing apoptosis and killing cells, particularly cancer cells in mammals. He has 1 patent to his name.

Career Highlights

Zhenyu Cheng is associated with Senesco Technologies, Inc., where he continues to advance his research in cancer therapies. His work is characterized by a commitment to developing innovative solutions that address critical health challenges.

Collaborations

Zhenyu collaborates with esteemed colleagues, including John E. Thompson and Zhong Sun, who contribute to his research endeavors. Their combined expertise enhances the potential impact of their work in the field of cancer research.

Conclusion

Zhenyu Cheng's innovative contributions to cancer research through his patent and collaboration with other experts underscore his commitment to improving treatment options for cancer patients. His work exemplifies the importance of innovation in the fight against cancer.